# The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.

> **NCT04026841** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 36 (estimated)

## Conditions studied

- Multiple Primary Lung Cancers

## Interventions

- **DRUG:** PD-1 antibody Sintilimab

## Key facts

- **NCT ID:** NCT04026841
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-30
- **Primary completion:** 2020-02-01
- **Final completion:** 2020-02-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04026841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04026841, "The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04026841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*